Companies → COFCO Biotechnology Co., Ltd.
Save to list
Remove

COFCO Biotechnology Co., Ltd.

China, Anhui, Bengbu
Description
by AI
COFCO Biotechnology Co., Ltd. engages in the research, development, production, sales, and servicing of enzymes, food additives, and sweeteners. Its products include citric acid, maltose, starch sugar, glucoamylase, glucose oxidase, catalase, hexokinase, and bidolase, which are used in industries, such as beer, vinegar, MSG, brewing enzyme, textiles, detergents, papermaking, printing, baking, and grain processing. The company mainly operates in China. COFCO Biotechnology Co., Ltd. is based in Beijing, China. COFCO Biotechnology Co., Ltd. is a subsidiary of COFCO Corporation.
Address:

Floor 7

Suite A

No.8 Middle Liang Square

Jianguo Mennei Da Street

Dongcheng Area

Beijing

No.343

Tushan Road

Yuhui District Bengbu

Anhui

233412 China

Revenue
Recent news:

Energy & Utilities Roundup: Market Talk

Find insight on Infratil, oil futures and more in the latest Market Talks covering Energy and Utilities.

Source: The Wall Street Journal Sep 9, 2025

Westin Desaru Coast Resort partners with CAYIN Technology for digital signage

The partnership involves the implementation of the CMS-WS server and CAYIN Signage Player.

Source: Hotel Management Network Sep 9, 2025

Nifty clocks fifth session of gains led by IT on Infosys buyback, US rate cut hopes

India's benchmark Nifty 50 closed higher for a fifth consecutive session on Tuesday, with gains led by information technology stocks on Infosys' share buyback plan and U.S. interest rate cut prospects. The Nifty 50 and the BSE Sensex gained 0.39% each to 24,868.6 and 81,101.32 points, respectively. IT jumped 2.8%, led by a 5% surge in Infosys after it announced plans to consider a share buyback on September 11.

Source: Reuters Sep 9, 2025

SZSE - Delayed Quote - CNY
000930.SZ
6.86 -0.29 (-4.06%)
At close March 23 07:00 UTC
Candle
Line
1M
6M
1Y
5Y
Financial Statistics
Valuation Measures
Current
Quarterly
As of 03/21/2026
Market Cap: 12.74 B
Enterprise Value: 14.37 B
Trailing P/E: 134.51
Forward P/E: 11.83
PEG Ratio (5yr expected): N/A
Price/Sales (ttm): 0.70
Price/Book (mrq): 1.19
Enterprise Value/Revenue: 0.79
Enterprise Value/EBITDA: 58.18
Financial Highlights
Profitability and Income Statement
Profit Margin: 0.52%
Return on Assets (ttm): 0.32%
Return on Equity (ttm): 0.97%
Revenue (ttm): 18.19 B
Net Income Avi to Common (ttm): 94.71 M
Diluted EPS (ttm): 0.05
Balance Sheet and Cash Flow
Total Cash (mrq): 2.52 B
Total Debt/Equity (mrq): 37.51%
Levered Free Cash Flow (ttm): 628.42 M
Disclaimer:

IndexBox is not affiliated with, associated with, or endorsed by this company in any way. The information provided on this page, including company details, is solely for informational purposes. IndexBox makes no representations or warranties about the accuracy or completeness of the information provided.

All data and information is provided “as is” for informational purposes only, and is not intended for trading purposes or financial, investment, tax, legal, accounting or other advice. Please consult your broker or financial representative to verify pricing before executing any trade. IndexBox is not an investment adviser, financial adviser or a securities broker. None of the data and information constitutes investment advice nor an offering, recommendation or solicitation by IndexBox to buy, sell or hold any security or financial product, and IndexBox makes no representation (and has no opinion) regarding the advisability or suitability of any investment.